Featured Research

from universities, journals, and other organizations

Molecular Therapeutics Advance Fight Against Brain Cancer

Date:
August 5, 2004
Source:
University Of Pennsylvania Medical Center
Summary:
An estimated 41,000 new cases of primary brain tumors are expected to be diagnosed in 2004, according to the American Brain Tumor Association. To further narrow the gap between diagnosis and effective therapy, physicians at the University of Pennsylvania Health System now offer several promising approaches to brain tumor treatment, including novel imaging for oncologic neurosurgery and refined genetic testing for tumors to better target treatment.

Philadelphia, PA -- An estimated 41,000 new cases of primary brain tumors are expected to be diagnosed in 2004, according to the American Brain Tumor Association. To further narrow the gap between diagnosis and effective therapy, physicians at the University of Pennsylvania Health System now offer several promising approaches to brain tumor treatment, including novel imaging for oncologic neurosurgery and refined genetic testing for tumors to better target treatment.

Through enhanced magnetic resonance imaging (MRI), newer and broader information is helping to better guide tumor removal. MRI is used to measure the anatomy and metabolism of tumors. This informs surgeons pre- and post-operatively with a three-dimensional map of tumor-associated blood flow to more precisely assess the full extent of tumor growth versus conventional imaging methods. "This novel approach helps guide surgery and assessment of treatment response," says Donald M. O'Rourke, M.D., Associate Professor of Neurosurgery. These novel imaging methods are leading to increased patient survival by allowing for greater tumor removal in a safe manner.

Neuroscientists are also ushering in a new era in which genetics will dictate treatment. In the 1990s researchers noted that a more favorable prognosis in patients with certain brain tumors, primarily oligodendrogliomas, was associated with a deletion of genes on chromosomes 1 and 19. This genetic loss translates into a significant life-expectancy gain for some patients and is therefore a robust predictor that post-surgery chemotherapy should be given to such patients.

Patients with the genetic deletion on chromosome 1 have a median survival in certain cases of about 10 years and respond particularly well to chemotherapy given immediately after surgery. Patients with the deletion have slower-growing tumors and show a better response to chemotherapy; whereas, those without the deletion have relatively faster-growing tumors and are less responsive to chemotherapy, so radiation therapy is required sooner. "Given the expected increase in the life-span of patients with this deletion, there is no need to give radiation therapy early in their treatment," explains O'Rourke.

The deletion can only be detected by genetic analysis. "Under the microscope these tumors can look identical, so there's no way of knowing the difference unless a genetic analysis is performed," explains O'Rourke.

Having the ability to provide such genetic testing to determine treatment is of benefit to patients. "The idea of using a genetic test to predict prognosis and select therapy, thereby deferring potentially deleterious treatment is tremendously attractive," says O'Rourke. "Penn's genetic testing is done in-house, so patients don't have to wait for the results." Further, there is no cost to the patient at this point since the tests are performed by the Neuro-oncology Program and supported by the Abramson Cancer Center at Penn. In addition, there is no requirement for additional blood samples, so results will be given more quickly with no need for follow-up visits.

Penn colleagues J. Carl Oberholtzer, MD, PhD, Department of Neuropathology and Myrna Rosenfeld, MD, PhD, Department of Neurology and Director of the Division of Neuro-oncology as well as Jaclyn Biegel, PhD, Director of Cytogenetics, Children's Hospital of Philadelphia, collaborated with O'Rourke on developing the genetic testing program. Dr. Biegel's laboratory performs the genetic test and has significant experience with genetic testing of brain tumors.

O'Rourke is also Director of the Human Brain Tumor Tissue Bank at Penn, one of only a few such dedicated banks in the United States. Tissue banks allow for the direct evaluation of human tumors and are one of the best ways to advance treatment options for gliomas and other human cancers. O'Rourke's basic research interests include finding new treatments for gliomas based on genetic alterations detected in tumors. He is currently investigating a variant of the epidermal growth factor receptor that is present in many primary glioblastomas to better understand the development of malignancy in the brain and how it relates to cancer cell division, survival, and movement.


Story Source:

The above story is based on materials provided by University Of Pennsylvania Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Pennsylvania Medical Center. "Molecular Therapeutics Advance Fight Against Brain Cancer." ScienceDaily. ScienceDaily, 5 August 2004. <www.sciencedaily.com/releases/2004/08/040805091248.htm>.
University Of Pennsylvania Medical Center. (2004, August 5). Molecular Therapeutics Advance Fight Against Brain Cancer. ScienceDaily. Retrieved September 15, 2014 from www.sciencedaily.com/releases/2004/08/040805091248.htm
University Of Pennsylvania Medical Center. "Molecular Therapeutics Advance Fight Against Brain Cancer." ScienceDaily. www.sciencedaily.com/releases/2004/08/040805091248.htm (accessed September 15, 2014).

Share This



More Health & Medicine News

Monday, September 15, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Respiratory Virus Spreads To Northeast, Now In 21 States

Respiratory Virus Spreads To Northeast, Now In 21 States

Newsy (Sep. 14, 2014) The respiratory virus Enterovirus D68, which targets children, has spread from the Midwest to 21 states. Video provided by Newsy
Powered by NewsLook.com
Shocker: Journalists Are Utterly Addicted To Coffee

Shocker: Journalists Are Utterly Addicted To Coffee

Newsy (Sep. 13, 2014) A U.K. survey found that journalists consumed the most amount of coffee, but that's only the tip of the coffee-related statistics iceberg. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins